MyFinsight
Home
About
Contact
algs: the income statement
Download
Download image
Unrealized gain on
available-for-sale securities
$35K
(-57.83%↓ Y/Y)
Comprehensive loss
-$31,502K
(-64.28%↓ Y/Y)
Other comprehensive
gain
$35K
(-57.83%↓ Y/Y)
Net loss
-$31,537K
(-63.75%↓ Y/Y)
Income tax provision
$56K
(-38.46%↓ Y/Y)
Loss before income
tax
-$31,481K
(-64.24%↓ Y/Y)
Interest and other
income, net
$1,085K
(12.67%↑ Y/Y)
Change in fair value of
2023 common warrants
$4,205K
Loss from operations
-$28,361K
(-40.88%↓ Y/Y)
Revenue from customers
$741K
(3800.00%↑ Y/Y)
Total operating
expenses
$29,102K
(35.99%↑ Y/Y)
General and
administrative
$5,165K
(11.65%↑ Y/Y)
Research and development
$23,937K
(42.70%↑ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
Aligos Therapeutics, Inc. (ALGS)
Aligos Therapeutics, Inc. (ALGS)